Increased VTE Risk for Men Starting Testosterone Therapy

Share this content:
Increased VTE Risk for Men Starting Testosterone Therapy
Increased VTE Risk for Men Starting Testosterone Therapy

THURSDAY, Dec. 1, 2016 (HealthDay News) -- Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within six months and declining thereafter, according to a study published online Nov. 30 in The BMJ.

Carlos Martinez, M.D., of the Institute for Epidemiology, Statistics and Informatics in Frankfurt, Germany, and colleagues reviewed data from 19,215 British patients with confirmed VTE. These men were compared with 909,530 age-matched patients in a control group.

Within the first six months of testosterone treatment, the rate ratio of VTE was 1.63 compared to those not taking the hormone, the researchers found. The rate ratios after more than six months' treatment and treatment cessation were 1.00 and 0.68, respectively.

"Our study suggests a transient increase in the risk of VTE that peaks during the first three to six months and declines gradually thereafter. Failure to investigate the timing of VTEs in relation to the duration of testosterone use could result in masking of an existing transient association," the authors write. "Future research is needed to confirm this temporal increase in the risk of VTE and to investigate the risk in first-time testosterone users and confirm the absence of risk with long-term use."

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cognitive Training Can Positively Affect Perception of Tinnitus

Cognitive Training Can Positively Affect Perception of Tinnitus

Researchers find computer-based program allows patients to cope better with tinnitus

Early Study Results Promising for Genital Herpes Vaccine

Early Study Results Promising for Genital Herpes Vaccine

Two-pronged approach tested on lab monkeys, guinea pigs

Type 1 Diabetes Tied to Gut Inflammation, Microbiota

Type 1 Diabetes Tied to Gut Inflammation, Microbiota

Type 1 diabetes patients exhibit different and distinct inflammation and gut microbiota

is free, fast, and customized just for you!

Already a member?

Sign In Now »